update: PARP inhibitor studies undergoing redesign

When the results from a Phase III study on PARP inhibitor iniparib (Sanofi-Aventis) proved disappointing, review of the results indicated areas of the research protocols that might be refined in order to further study the drug more closely. Based on Phase II studies of iniparib, the expectations for iniparib to be effective for patients with BRCA1/2 mutations were high. Results failed to show the expected results.

Because further yet unidentified subtypes of triple negative and BRCA1/2 breast cancers might play a role in determining the patient population for whom the drug might be effective, researchers are busy redesigning the studies in the hope of identifying those subtypes. Other changes are also under review in planning the updated protocols.

The good news is that PARP inhibitors seem to have a chance at benefiting breast and other cancers.

PARP inhibitors: the story is still unfolding. By Debu Tripathy, MD. In CancerNetwork, Commentary: Oncology. Vol. 25 No. 11, 10-12-11

5 6 7 8
© 2004–2011 Donna Peach. All rights reserved.


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s